Form D · Biotechnology

Ambrosia Biosciences Inc.

Boulder, CO · CIK 0002032941

Offering snapshot reported Aug 20, 2024 · SEC filing

Reported sold
$16M
Offering amount: $25M
Investors reported
7
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jul 23, 2024
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$7.98M$16MAug 7, 2024: $12,500,000.00Aug 7, 2024Aug 20, 2024: $15,955,000.00Aug 20, 2024

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$12,500,000 → $15,955,000
  • Reported investors6 → 7

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 20, 2024Amendment$15,955,000$3,455,000vs Aug 7, 20247SEC filing
Aug 7, 2024Initial$12,500,000No comparison6SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-520756

Source: Form D, filed Aug 20, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Kyle Lefkoff Director
William S. Marshall Director
John S. Orwin Director
David S. Snitman Director
Nicholas Traggis Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1941 Pearl Street Suite 300
Boulder, CO, 80302